Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics
GET POWR RATINGS... FREE!
MDGL Stock Price Chart Interactive Chart >
MDGL Price/Volume Stats
|Current price||$107.94||52-week high||$142.62|
|Prev. close||$106.81||52-week low||$97.00|
|Day high||$108.34||Avg. volume||165,574|
|50-day MA||$122.44||Dividend yield||N/A|
|200-day MA||$119.23||Market Cap||1.79B|
Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.
MDGL Latest News Stream
|Loading, please wait...|
MDGL Latest Social Stream
View Full MDGL Social Stream
Latest MDGL News From Around the Web
Below are the latest news stories about Madrigal Pharmaceuticals Inc that investors may wish to consider to help them evaluate MDGL as an investment opportunity.
WEST CONSHOHOCKEN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences: 42nd Annual Goldman Sachs Global Healthcare Conference Fireside chat at 9:40 a.m. ET on Thursday, June 1
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
WEST CONSHOHOCKEN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today that members of its executive team, including Paul Friedman, M.D., Chief Executive Officer, Becky Taub, M.D., Chief Medical Officer and President of Research and Development, Remy Sukhija, Senior Vice President and Chief Commercial Officer and Alex Howarth, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 4:00 pm ET. The fireside chat will be webcast live and can be accessed in the Investor Relat...
Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We are pleased with the substantial progress the Company made in 2020, particularly in light of the significant challenges resulting from the COVID-19 pandemic,” stated Paul Friedman, M.D., Chief Executive Officer of Madrigal. “We completed enrollment in the Company’s Phase 3 MAESTRO-NAFLD-1 trial in less than 12 months, and we also made significant progress in enrollment of our Phase 3 MAESTRO-NASH trial.” Dr. Friedman continued, “We advanced the development of Madrigal’s commercial capabilities in 2020, with Remy Sukhija joining the Company as Senior Vice President and Chief Commercial Officer. R...
MDGL Price Returns